Literature DB >> 22753908

Timing of epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung cancer with EGFR mutations.

Teresa Moran1, Lecia V Sequist.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22753908     DOI： 10.1200/JCO.2012.43.1858

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN： 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  15 in total

1.  Gefitinib frequently induces liver damage in patients with lung adenocarcinoma previously treated by chemotherapy.

Authors:  Yasoo Sugiura; Etsuo Nemoto; Osamu Kawai; Yasuyuki Ohkubo; Hisae Fusegawa; Shizuka Kaseda
Journal:  Lung Cancer (Auckl)       Date:  2013-06-08

Review 2.  Clinical management of epidermal growth factor receptor mutation-positive non-small cell lung cancer patients after progression on previous epidermal growth factor receptor tyrosine kinase inhibitors: the necessity of repeated molecular analysis.

Authors:  José Luís González-Larriba; Martín Lázaro-Quintela; Manuel Cobo; Manuel Dómine; Margarita Majem; Rosario García-Campelo
Journal:  Transl Lung Cancer Res       Date:  2017-12

3.  Cutaneous metastasis: a rare herald of a silent cancer.

Authors:  Jonathan Hussain; Donevan Westerveld; Maryam Sattari
Journal:  BMJ Case Rep       Date:  2016-01-18

4.  Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy.

Authors:  Zhuanglin Li; Mingxue Wang; Xuejing Yao; Wenting Luo; Yaocheng Qu; Deling Yu; Xue Li; Jianmin Fang; Changjiang Huang
Journal:  Target Oncol       Date:  2019-02       Impact factor: 4.493

Review 5.  Acquired resistance to TKIs in solid tumours: learning from lung cancer.

Authors:  D Ross Camidge; William Pao; Lecia V Sequist
Journal:  Nat Rev Clin Oncol       Date:  2014-07-01       Impact factor: 66.675

6.  Reversion of erlotinib-acquired resistance twice by chemotherapy: a case report.

Authors:  Fei-fei Teng; Jian-dong Zhang; Xue Meng; Jin-ming Yu
Journal:  Cancer Biol Ther       Date:  2013-12-06       Impact factor: 4.742

7.  Molecularly targeted therapies in non-small-cell lung cancer annual update 2014.

Authors:  Daniel Morgensztern; Meghan J Campo; Suzanne E Dahlberg; Robert C Doebele; Edward Garon; David E Gerber; Sarah B Goldberg; Peter S Hammerman; Rebecca S Heist; Thomas Hensing; Leora Horn; Suresh S Ramalingam; Charles M Rudin; Ravi Salgia; Lecia V Sequist; Alice T Shaw; George R Simon; Neeta Somaiah; David R Spigel; John Wrangle; David Johnson; Roy S Herbst; Paul Bunn; Ramaswamy Govindan
Journal:  J Thorac Oncol       Date:  2015-01       Impact factor: 15.609

8.  Cost-effectiveness of multiplexed predictive biomarker screening in non-small-cell lung cancer.

Authors:  Dorothy Romanus; Stephanie Cardarella; David Cutler; Mary Beth Landrum; Neal I Lindeman; G Scott Gazelle
Journal:  J Thorac Oncol       Date:  2015-04       Impact factor: 15.609

Review 9.  Irreversible EGFR-TKIs: dreaming perfection.

Authors:  Lorenza Landi; Federico Cappuzzo
Journal:  Transl Lung Cancer Res       Date:  2013-02

Review 10.  The war on cancer: are we winning?

Authors:  M J Duffy
Journal:  Tumour Biol       Date:  2013-04-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.